Search
Search Results
-
Progress in Targeting KRAS Directly
RAS research has entered the world of translational and clinical science. Progress has been based on our appreciation of the role of RAS mutations in...
-
KRAS (Kirsten rat sarcoma) in modern oncology—The molecular pathological point of view
The Rat sarcoma protein (RAS) was the first proto-oncogene to be discovered and is one of the best researched tumor drivers today. The RAS protein...
-
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors
Recent clinical development of KRAS inhibitors has heightened interest in the genomic landscape of KRAS -altered cancers. We performed a pan-cancer...
-
YB-1 activating cascades as potential targets in KRAS-mutated tumors
Y‑box binding protein‑1 (YB-1) is a multifunctional protein that is highly expressed in human solid tumors of various entities. Several cellular...
-
From bench to bedside: current development and emerging trend of KRAS-targeted therapy
Kirsten rat sarcoma 2 viral oncogene homolog ( KRAS ) is the most frequently mutated oncogene in human cancers with mutations predominantly occurring...
-
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Among the most common molecular alterations detected in non-small-cell lung cancer (NSCLC) are mutations in Kristen Rat Sarcoma viral oncogene...
-
In Silico Evaluation of Bioactive Compounds of Citrullus lanatus as Potential Noncovalent KRAS Inhibitors in the Treatment of Human Cancer
Cancer deaths and other dangerous symptoms associated with it make the search for therapies to combat it a necessity. The use of drugs has been...
-
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) is the most frequently mutated oncogene, occurring in a variety of tumor types. Targeting KRAS...
-
An Updated Review on KRAS Mutation in Lung Cancer (NSCLC) and Its Effects on Human Health
The largest cause of cancer-related fatalities worldwide is lung cancer. In its early stages, lung cancer often exhibits no signs or symptoms. Its...
-
The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
The RAS oncogene is both the most frequently mutated oncogene in human cancer and the first confirmed human oncogene to be discovered in 1982. After...
-
Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions
Oncogenic driver mutations have implications that extend beyond cancer cells themselves. Aberrant tumour cell signalling has various effects on the...
-
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
RAS and MYC rank amongst the most commonly altered oncogenes in cancer, with RAS being the most frequently mutated and MYC the most amplified. The...
-
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels. Kirsten rat sarcoma ( KRAS ) is a commonly mutated oncogene in...
-
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Across a broad range of human cancers, gain-of-function mutations in RAS genes ( HRAS , NRAS , and KRAS ) lead to constitutive activity of oncoproteins...
-
Capturing the primordial Kras mutation initiating urethane carcinogenesis
The environmental carcinogen urethane exhibits a profound specificity for pulmonary tumors driven by an oncogenic Q 61 L/R mutation in the gene Kras ....
-
Emerging strategies to target RAS signaling in human cancer therapy
RAS mutations ( HRAS , NRAS , and KRAS ) are among the most common oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells...
-
-
Structural basis for SHOC2 modulation of RAS signalling
The RAS–RAF pathway is one of the most commonly dysregulated in human cancers
1 –3 . Despite decades of study, understanding of the molecular mechanisms...
-
Rare molecular subtypes of lung cancer
Oncogenes that occur in ≤5% of non-small-cell lung cancers have been defined as ‘rare’; nonetheless, this frequency can correspond to a substantial...
-
K-Ras prenylation as a potential anticancer target
KRAS is one of the most commonly mutated oncogene and a negative predictive factor for a number of targeted therapies. Therefore, the development of...
